LOGIN  |  REGISTER
Astria Therapeutics
Recursion

NEXGEL to Participate in the iAccess Alpha Virtual Best Ideas Spring Investment Conference on March 25-26th, 2025

March 13, 2025 | Last Trade: US$1.58 0.05 -3.07

LANGHORNE, Pa., March 13, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will present at the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025 on March 25 and 26, 2025.

iAccess Alpha Virtual Conference Details:
Date: March 25-26, 2025
Presentation Day and Time: Tuesday, March 25th at 9:30 a.m. ET
Webcast: https://www.webcaster4.com/Webcast/Page/3083/52115

To schedule a one-on-one investor meeting with Mr. Levy, please contact your representatives at iAccess or email KCSA Strategic Communications at This email address is being protected from spambots. You need JavaScript enabled to view it..

About NEXGEL, Inc.

NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.

Investor Contacts:

Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page